About Keith Crandell
Keith Crandell is a 10% owner at Boundless Bio.
Form D filings name Keith Crandell as a director at Vizgen and Ultivue.
Keith Crandell reports to the SEC as a director or major shareholder of 46 public companies, including Kardigan (KARD), 908 Devices (MASS) and Seaport Therapeutics (SPTX).
Keith Crandell first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Keith Crandell in the role, so the role may have started earlier or lasted longer.
BI
KI
Kardigan, Inc.
Director and 10% owner
2026 · Public company (KARD)
9I
908 Devices Inc.
Director and 10% owner
2020 – 2026 · Public company (MASS)
SI
LI
Lyell Immunopharma, Inc.
10% owner
2021 – 2026 · Public company (LYEL)
TC
Twist Bioscience Corp
Director and 10% owner
2018 – 2026 · Public company (TWST)
MI
NI
Neumora Therapeutics, Inc.
10% owner
2023 – 2025 · Public company (NMRA)
PI
Prime Medicine, Inc.
10% owner
2022 – 2025 · Public company (PRME)
MI
Maze Therapeutics, Inc.
10% owner
2025 · Public company (MAZE)
RI
Rapport Therapeutics, Inc.
10% owner
2024 · Public company (RAPP)
SI
Sana Biotechnology, Inc.
10% owner
2021 – 2024 · Public company (SANA)
DC
DA32 Life Science Tech Acquisition Corp.
Director and 10% owner
2021 – 2023 · Public company (DALS)
QC
Quanterix Corp
Director and 10% owner
2017 – 2023 · Public company (QTRX)
CI
Codiak BioSciences, Inc.
10% owner
2020 – 2022 · Public company (CDAK)
VI
Vir Biotechnology, Inc.
10% owner
2019 – 2022 · Public company (VIR)
EI
Erasca, Inc.
10% owner
2021 · Public company (ERAS)
BI
Beam Therapeutics Inc.
10% owner
2020 – 2021 · Public company (BEAM)
VI
Verve Therapeutics, Inc.
10% owner
2021 · Public company (VERV)
KI
Karuna Therapeutics, Inc.
10% owner
2019 – 2021 · Public company (KRTX)
MI
Metacrine, Inc.
10% owner
2020 · Public company (MTCR)
DI
Denali Therapeutics Inc.
10% owner
2017 – 2019 · Public company (DNLI)
SI
Syros Pharmaceuticals, Inc.
10% owner
2016 – 2019 · Public company (SYRS)
AC
Adesto Technologies Corp.
Director and 10% owner
2015 – 2019 · Public company (IOTS)
QI
Q32 Bio Inc.
10% owner
2018 – 2019 · Public company (QTTB)
SI
Sienna Biopharmaceuticals, Inc.
10% owner
2017 – 2019 · Public company (SNNA)
GI
Gossamer Bio, Inc.
10% owner
2019 · Public company (GOSS)
SC
Scholar Rock Holding Corp
10% owner
2018 · Public company (SRRK)
UI
Unity Biotechnology, Inc.
10% owner
2018 · Public company (UBX)
PI
Pulmatrix, Inc.
10% owner
2015 – 2018 · Public company (PULM)
XI
Xtera Communications, Inc.
10% owner
2015 – 2016 · Public company (XCOM)
II
Impinj Inc.
10% owner
2016 · Public company (PI)
PI
Phaserx, Inc.
10% owner
2016 · Public company (PZRX)
JI
Juno Therapeutics, Inc.
10% owner
2014 – 2016 · Public company (JUNO)
VI
Vbi Vaccines Inc.
10% owner
2014 – 2015 · Public company (VBIV)
SI
Sage Therapeutics, Inc.
10% owner
2014 – 2015 · Public company (SAGE)
BI
Bellerophon Therapeutics, Inc.
10% owner
2015 · Public company (BLPH)
AI
Agios Pharmaceuticals, Inc.
10% owner
2013 – 2015 · Public company (AGIO)
RI
Receptos, Inc.
10% owner
2013 – 2014 · Public company (RCPT)
AI
Achaogen, Inc.
10% owner
2014 · Public company (AKAO)
FI
Fate Therapeutics Inc.
10% owner
2013 · Public company (FATE)
BI
bluebird bio, Inc.
10% owner
2013 · Public company (BLUE)
KI
Kythera Biopharmaceuticals Inc.
10% owner
2012 · Public company (KYTH)
NI
NeurogesX Inc
10% owner
2007 – 2011 · Public company (NGSX)
TI
Trubion Pharmaceuticals, Inc
10% owner
2006 – 2010 · Public company (TRBN)
CI
Celebrate Express, Inc.
Director and 10% owner
2006 – 2008 · Public company (BDAY)
Key Colleagues at Startups
The people Keith Crandell works with at each company, as listed on that company's latest Form D.
Vizgen, Inc. · Form D, Jan 12, 2026
AJ
Andrea Jackson
Director
SL
Simona Levi
Executive officer
RC
Robert Carson
President and CEO, director
MP
Matthew Posard
Director
CU
Christian Uhrich
Director
DW
David Walt
Director
Ultivue, Inc. · Form D, Jul 25, 2024
